Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report) shares traded down 2% on Tuesday . The company traded as low as $9.27 and last traded at $9.28. 510,457 shares were traded during mid-day trading, an increase of 51% from the average session volume of 337,931 shares. The stock had previously closed at $9.47.
Silverback Therapeutics Trading Up 1.3 %
The business's 50 day moving average price is $8.04 and its two-hundred day moving average price is $5.87. The company has a market capitalization of $338.95 million, a price-to-earnings ratio of -3.88 and a beta of 0.60.
Institutional Investors Weigh In On Silverback Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its position in Silverback Therapeutics by 6.3% during the 1st quarter. Renaissance Technologies LLC now owns 330,600 shares of the company's stock worth $2,152,000 after buying an additional 19,600 shares during the period. BlackRock Inc. boosted its position in Silverback Therapeutics by 23.8% during the 1st quarter. BlackRock Inc. now owns 1,118,565 shares of the company's stock worth $7,282,000 after buying an additional 215,020 shares during the period. Bank of America Corp DE boosted its position in Silverback Therapeutics by 85.1% during the 1st quarter. Bank of America Corp DE now owns 24,500 shares of the company's stock worth $159,000 after buying an additional 11,261 shares during the period. HRT Financial LP acquired a new stake in Silverback Therapeutics during the 1st quarter worth approximately $883,000. Finally, HighTower Advisors LLC acquired a new stake in Silverback Therapeutics during the 1st quarter worth approximately $72,000. 74.89% of the stock is currently owned by institutional investors and hedge funds.
About Silverback Therapeutics
(
Get Free Report)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Recommended Stories
Before you consider Silverback Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silverback Therapeutics wasn't on the list.
While Silverback Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
